Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu(Massachusetts General Hospital), Richard S. Finn(University of California, Los Angeles), Julien Edeline(Centre Eugène Marquis), Stéphane Cattan(Hôpital Claude Huriez), Sadahisa Ogasawara(Chiba University), Daniel H. Palmer(University of Liverpool), Chris Verslype, Vittorina Zagonel(Istituto Oncologico Veneto), Lætitia Fartoux(Sorbonne Université), Arndt Vogel(Medizinische Hochschule Hannover), Debashis Sarker(King's College Hospital), Gontran Verset(Erasmus Hospital), Stephen L. Chan(Chinese University of Hong Kong), Jennifer J. Knox(Princess Margaret Cancer Centre), Bruno Daniele(Azienda Ospedaliera G.Rummo), Andrea L. Webber(Merck & Co., Inc., Rahway, NJ, USA (United States)), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Junshui Ma(Merck & Co., Inc., Rahway, NJ, USA (United States)), Abby B. Siegel(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ann‐Lii Cheng(National Taiwan University Hospital), Masatoshi Kudo(Kindai University), Angela Alistar, Jamil Asselah, Jean‐Frédéric Blanc, Ivan Borbath, Timothy Lewis Cannon, Ki Y. Chung, Allen Lee Cohn, David Cosgrove, Nevena Damjanov, Mukul Gupta, Yoshivasu Karino, Mark Karwal, Andreas Kaubisch, Robin Kate Kelley, Jena-Luc Van Laethem, Timothy Larson, James Lee, Daneng Li(National Taiwan University Hospital), Atisha Manhas, Gulam A. Manji, Kazushi Numata, Benjamin M. Parsons, Andrew Scott Paulson, Carmine Pinto, Robert A. Ramirez, Suresh Ratnam, Magnus Rizell, Olivier Rosmorduc, Yvonne H. Sada(Chiba University), Yutaka Sasaki, Per Stål, Simone I. Strasser, Joerg Trojan, Gina M. Vaccaro, Hans Van Vlierberghe, Alan Weiss, Karl-Heinz Weiss, Tatsuya Yamashita
Cited by 2,523
Abstract
Related Papers
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro et al.|New England Journal of Medicine|2008|12.9k
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al.|New England Journal of Medicine|2016|10k